SEC Form 4 · accession 0001179110-18-002534

ABBOTT LABORATORIES · ABT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Vice President, Controller

Period of report

Feb 16, 2018

Accepted (ET)

Feb 21, 2018 · 6:49 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000001800

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common shares without par value^F1	Feb 16, 2018	A	20,030	$0.00	A	108,367	D
Common shares without par value^F2	holding	—	—		—	17,004	I	Profit Sharing Trust
Common shares without par value^F3	holding	—	—		—	500	I	By Daughter
Common shares without par value^F3	holding	—	—		—	500	I	By Daughter

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option (right to buy)^F4	$59.94	Feb 16, 2018	A	110,146	A	Feb 16, 2019	Feb 15, 2028	Common shares	110,146	110,146	D

F1These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2Balance in the Abbott Laboratories Stock Retirement Trust as of February 16, 2018.
F3The reporting person disclaims beneficial ownership of all securities held by his daughter.
F4Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021.